New Zealand markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.86+0.11 (+1.63%)
At close: 01:00PM EST
6.83 -0.03 (-0.44%)
After hours: 04:42PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 497.36M
Enterprise value 568.25M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.36
Price/book (mrq)74.89
Enterprise value/revenue 7.89
Enterprise value/EBITDA -3.04

Trading information

Stock price history

Beta (5Y monthly) 0.31
52-week change 3-20.97%
S&P500 52-week change 3-13.51%
52-week high 39.13
52-week low 33.28
50-day moving average 37.55
200-day moving average 36.24

Share statistics

Avg vol (3-month) 31.11M
Avg vol (10-day) 31.08M
Shares outstanding 573.68M
Implied shares outstanding 6N/A
Float 867.42M
% held by insiders 10.73%
% held by institutions 187.79%
Shares short (14 Nov 2022) 413.7M
Short ratio (14 Nov 2022) 411.38
Short % of float (14 Nov 2022) 422.47%
Short % of shares outstanding (14 Nov 2022) 418.59%
Shares short (prior month 13 Oct 2022) 413.33M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-267.31%

Management effectiveness

Return on assets (ttm)-44.75%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)72.06M
Revenue per share (ttm)1.26
Quarterly revenue growth (yoy)31.70%
Gross profit (ttm)-41.74M
EBITDA -192.06M
Net income avi to common (ttm)-243.29M
Diluted EPS (ttm)-6.24
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)189.34M
Total cash per share (mrq)2.57
Total debt (mrq)544.91M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.18
Book value per share (mrq)-4.10

Cash flow statement

Operating cash flow (ttm)-190.06M
Levered free cash flow (ttm)-144.85M